Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25822215 | 1.00 | CRBN (0.49) | CRBNDDB1ALDH1A1KMT2APOLB | |
| SCHEMBL25029440 | 0.89 | CRBN (0.51) | CRBNDDB1POLB | |
| SCHEMBL31712325 | 0.88 | CRBN (0.49) | CRBNDDB1POLB | |
| SCHEMBL27194319 | 0.86 | CRBN (0.45) | CRBNDDB1ALDH1A1POLB | |
| SCHEMBL30066283 | 0.86 | CRBN (0.45) | CRBNDDB1ALDH1A1POLB | |
| SCHEMBL25823256 | 0.86 | CRBN (0.48) | CRBNDDB1POLB | |
| SCHEMBL30475505 | 0.86 | CRBN (0.48) | CRBNDDB1POLB | |
| SCHEMBL24671220 | 0.86 | CRBN (0.45) | CRBNDDB1ALDH1A1POLB | |
| SCHEMBL25190770 | 0.85 | CRBN (0.45) | CRBNDDB1POLB | |
| SCHEMBL24670689 | 0.85 | CRBN (0.44) | CRBNDDB1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2025049820-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-116322700-B | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-08-20 | — | — | CN | disclosed |
| CN-116322700-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2023-06-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | CRBN 207/4885DDB1 3932/4885ALDH1A1 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.